Surpassing Expectations: Increasing Deal Value Through Better Drug Value Propositions
Executive Summary
By failing to properly develop and articulate a strong, payor-oriented value proposition for their drug candidates, biopharmaceutical companies are shortchanging themselves and stunting the value of their assets, and as a result missing out on more lucrative partnering deals.